$OMER
OMEROS CORP Stock $omer

$omer Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000128581916000017 Filed on May 10, 2016

Income Statement

Concept	2016 Q2	2016 Q1	2015 Q1
Revenue	$10.00M	$7.419M	$388.0K
YoY Change	213.9%	1812.11%	288.0%
Cost Of Revenue	$327.0K	$327.0K	$11.00K
YoY Change	-10.41%	2872.73%
Gross Profit	$9.677M	$7.092M	$377.0K
YoY Change	242.91%	1781.17%	277.0%
Gross Profit Margin	96.73%	95.59%	97.16%
Selling, General & Admin	$10.38M	$11.11M	$8.990M
YoY Change	31.56%	23.58%	138.46%
% of Gross Profit	107.26%	156.66%	2384.62%
Research & Development	$10.23M	$15.43M	$9.318M
YoY Change	-6.14%	65.64%	-22.46%
% of Gross Profit	105.72%	217.63%	2471.62%
Depreciation & Amortization	$70.00K	$50.00K	$60.00K
YoY Change	40.0%	-16.67%	-25.0%
% of Gross Profit	0.72%	0.71%	15.92%
Operating Expenses	$20.93M	$26.87M	$18.32M
YoY Change	9.29%	46.69%	16.05%
Operating Profit	-$10.93M	-$19.45M	-$17.93M
YoY Change	-31.55%	8.49%	14.32%
Interest Expense	$1.857M	$1.375M	$957.0K
YoY Change	98.19%	43.68%	42.41%
% of Operating Profit
Other Income/Expense, Net	$174.0K	$288.0K	$218.0K
YoY Change	-22.32%	32.11%	-176.22%
Pretax Income	-$12.61M	-$20.54M	-$18.67M
YoY Change	-24.4%	10.02%	12.2%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$12.61M	-$20.54M	-$18.67M
YoY Change	-24.39%	10.02%	12.18%
Net Earnings / Revenue	-126.07%	-276.84%	-4811.6%
Basic Earnings Per Share
Diluted Earnings Per Share	-$321.8K	-$536.0K	-$511.8K
COMMON SHARES
Basic Shares Outstanding	39.14M shares	38.26M shares	37.80M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q2	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.20M	$13.20M	$70.10M
YoY Change	-58.75%	-81.17%	34.29%
Cash & Equivalents	$4.589M	$978.0K	$1.441M
Short-Term Investments	$16.60M	$12.30M	$68.60M
Other Short-Term Assets	$2.300M	$2.500M	$116.0K
YoY Change	2029.63%	2055.17%	-18.88%
Inventory	$1.780M	$1.972M	$566.0K
Prepaid Expenses	$2.282M	$2.460M	$1.784M
Receivables	$8.800M	$6.600M	$500.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$34.11M	$24.32M	$73.07M
YoY Change	-39.83%	-66.71%	34.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.251M	$898.0K	$727.0K
YoY Change	58.56%	23.52%	-26.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$73.00K	$73.00K	$439.0K
YoY Change	-85.04%	-83.37%	64.42%
Total Long-Term Assets	$12.00M	$11.65M	$1.845M
YoY Change	513.65%	531.44%	-4.65%
TOTAL ASSETS
Total Short-Term Assets	$34.11M	$24.32M	$73.07M
Total Long-Term Assets	$12.00M	$11.65M	$1.845M
Total Assets	$46.11M	$35.97M	$74.91M
YoY Change	-21.37%	-51.98%	33.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.420M	$5.332M	$4.611M
YoY Change	33.99%	15.64%	-6.39%
Accrued Expenses	$10.45M	$12.12M	$6.438M
YoY Change	54.68%	88.26%	21.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$193.0K	$69.00K	$9.019M
YoY Change	-97.92%	-99.23%
Total Short-Term Liabilities	$16.07M	$17.52M	$20.07M
YoY Change	-20.06%	-12.69%	96.13%
LONG-TERM LIABILITIES
Long-Term Debt	$69.83M	$49.97M	$23.91M
YoY Change	225.15%	109.04%	-25.79%
Other Long-Term Liabilities	$9.200M	$9.200M	$9.100M
YoY Change	1.1%	1.1%	8.33%
Total Long-Term Liabilities	$69.83M	$49.97M	$23.91M
YoY Change	225.15%	109.04%	-25.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.07M	$17.52M	$20.07M
Total Long-Term Liabilities	$69.83M	$49.97M	$23.91M
Total Liabilities	$85.90M	$67.49M	$43.97M
YoY Change	106.62%	53.49%	3.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$436.3M	-$423.7M	-$346.7M
YoY Change	20.06%	22.2%	27.93%
Common Stock	$393.0K	$391.0K	$378.0K
YoY Change	3.69%	3.44%	11.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$49.00M	-$40.74M	$21.85M
YoY Change
Total Liabilities & Shareholders Equity	$46.11M	$35.97M	$74.91M
YoY Change	-21.37%	-51.98%	33.61%

Cashflow Statement

Concept	2016 Q2	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	-$12.61M	-$20.54M	-$18.67M
YoY Change	-24.39%	10.02%	12.18%
Depreciation, Depletion And Amortization	$70.00K	$50.00K	$60.00K
YoY Change	40.0%	-16.67%	-25.0%
Cash From Operating Activities	-$12.79M	-$16.63M	-$17.48M
YoY Change	-22.67%	-4.85%	56.89%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	$0.00	$0.00
YoY Change	-72.73%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$4.380M	$14.63M	-$62.09M
YoY Change	-122.19%	-123.56%	59.57%
Cash From Investing Activities	-$4.410M	$14.63M	-$62.09M
YoY Change	-122.48%	-123.57%	59.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$7.500K	$79.10M
YoY Change		-99.99%	109.26%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	20.82M	$1.609M	$80.65M
YoY Change	-1167.69%	-98.01%	63.82%
NET CHANGE
Cash From Operating Activities	-12.79M	-$16.63M	-$17.48M
Cash From Investing Activities	-4.410M	$14.63M	-$62.09M
Cash From Financing Activities	20.82M	$1.609M	$80.65M
Net Change In Cash	3.620M	-$387.0K	$1.087M
YoY Change	220.35%	-135.6%	-233.05%
FREE CASH FLOW
Cash From Operating Activities	-$12.79M	-$16.63M	-$17.48M
Capital Expenditures	-$30.00K	$0.00	$0.00
Free Cash Flow	-$12.76M	-$16.63M	-$17.48M
YoY Change	-22.34%	-4.85%	56.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001285819
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39135054	shares
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	OMEROS CORP
CY2016Q1	dei	Trading Symbol TradingSymbol	OMER
CY2015Q4	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	1108000	USD
CY2016Q1	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	2061000	USD
CY2015Q4	omer	Accrued Contract Research Costs AccruedContractResearchCosts	2973000	USD
CY2016Q1	omer	Accrued Contract Research Costs AccruedContractResearchCosts	3260000	USD
CY2015Q1	omer	Classof Warrantor Right Exercised During Period ClassofWarrantorRightExercisedDuringPeriod	126000	shares
CY2015Q1	omer	Proceedsfrom Stock Optionsand Warrants Exercised ProceedsfromStockOptionsandWarrantsExercised	1576000	USD
CY2016Q1	omer	Proceedsfrom Stock Optionsand Warrants Exercised ProceedsfromStockOptionsandWarrantsExercised	1609000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6428000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5332000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9752000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12120000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2400000	USD
CY2016Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3232000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	376528000	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	382548000	USD
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9526529	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9302348	shares
CY2015Q4	us-gaap	Assets Assets	48995000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1441000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1365000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	978000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1087000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-387000	USD
CY2016Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	13200000	USD
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	749250	shares
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Assets Assets	35972000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	37146000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	24322000	USD
CY2015Q4	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	26898000	USD
CY2016Q1	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	12266000	USD
CY2015Q4	us-gaap	Cash Cash	1400000	USD
CY2016Q1	us-gaap	Cash Cash	978000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	354000	USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38040891	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39119154	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38040891	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39119154	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	380000	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	391000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18669000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20539000	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	11000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	327000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9207000	USD
CY2016Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9220000	USD
CY2015Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	55000	USD
CY2016Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	53000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2590000	USD
CY2016Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2544000	USD
CY2016Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	16600000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8989000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11110000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2170000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1272000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1500000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-725000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	420000	USD
CY2015Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	146000	USD
CY2016Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	129000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	957000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	1375000	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	745000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	776000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	221000	USD
CY2016Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	176000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	472000	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	1972000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	93000	USD
CY2016Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	104000	USD
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	158000	USD
CY2016Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1692000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48995000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35972000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16253000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	17521000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	73000	USD
CY2016Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	69000	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	49769000	USD
CY2016Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	49973000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80652000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1609000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-62089000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14632000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17476000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16628000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-18669000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-20539000	USD
CY2016Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	18318000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	26871000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17930000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19452000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	681000	USD
CY2016Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1023000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	219000	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	73000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	218000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	288000	USD
CY2015Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	212000	USD
CY2016Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	213000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4900000	USD
CY2015Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	79389000	USD
CY2016Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	18000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1894000	USD
CY2016Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2460000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	79100000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	79076000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2015Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	17300000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	14650000	USD
CY2015Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1400000	USD
CY2016Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7500	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	951000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	898000	USD
CY2015Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	6517000	USD
CY2016Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	6646000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9318000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15434000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	10679000	USD
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	10679000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-403142000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-423681000	USD
CY2015Q1	us-gaap	Revenue From Grants RevenueFromGrants	150000	USD
CY2016Q1	us-gaap	Revenue From Grants RevenueFromGrants	173000	USD
CY2015Q1	us-gaap	Revenues Revenues	388000	USD
CY2016Q1	us-gaap	Revenues Revenues	7419000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	238000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	7246000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2517000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4422000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6486712	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.09
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	27929	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	14.51
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1349055	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	65720000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8310235	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9302348	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.97
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.40
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	64505000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	9012412	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.30
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.87
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.31
CY2015Q1	us-gaap	Share Price SharePrice	20.03
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	53722000	USD
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y5M30D
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y5M45D
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y5M15D
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3400000	shares
CY2016Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	749250	shares
CY2016Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	329013	shares
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-26234000	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	-40742000	USD
CY2015	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2016Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36483559	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38317084	shares
CY2016Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Organization</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Our first drug product OMIDRIA was approved by the United States (U.S.) Food and Drug Administration (FDA) for use during cataract surgery or intraocular lens replacement. We broadly launched OMIDRIA in the U.S. in April 2015.</font></div></div>
CY2016Q1	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales, Net</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record revenue from OMIDRIA product sales when the product is delivered to our wholesalers.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales are recorded net of estimated chargebacks and rebates, wholesaler distribution fees and estimated product returns. Accruals or allowances are established for these deductions when revenue is recognized, and actual amounts incurred are offset against the applicable accruals and allowances. We reflect each of these accruals or allowances as either a reduction in the related accounts receivable or as an accrued liability, depending on how the accrual or allowance is settled. </font></div></div>
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001285819-16-000017-index-headers.html	Edgar Link	pending
0001285819-16-000017-index.html	Edgar Link	pending
0001285819-16-000017.txt	Edgar Link	pending
0001285819-16-000017-xbrl.zip	Edgar Link	pending
ex121_2016331.htm	Edgar Link	pending
ex311_2016331.htm	Edgar Link	pending
ex312_2016331.htm	Edgar Link	pending
ex321_2016331.htm	Edgar Link	pending
ex322_2016331.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
omer-20160331.xml	Edgar Link	completed
omer-20160331.xsd	Edgar Link	pending
omer-20160331x10q.htm	Edgar Link	pending
omer-20160331_cal.xml	Edgar Link	unprocessable
omer-20160331_def.xml	Edgar Link	unprocessable
omer-20160331_lab.xml	Edgar Link	unprocessable
omer-20160331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OMER
OMEROS CORP Stock $omer

2016 Q2 Form 10-Q Financial Statement

#000128581916000017 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER OMEROS CORP Stock $omer

2016 Q2 Form 10-Q Financial Statement

#000128581916000017 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER
OMEROS CORP Stock $omer